有奖答题🎁｜12月临床药理小测试～5

A patient suffering from refractory B-cell precursor acute lymphoblastic leukemia (ALL) requires treatment. After considering all treatment options, a decision is made to use a novel therapy that differs from CAR-T, but shares a common goal to bring cytotoxic T cells into close contact with their intended cancer cell targets. Which of the following has this mechanism of action?

A. atezolizumab (anti-PD-L1)

B. blinatumomab (BiTE)

C. rituximab

D. tocilizumab

----------------------------------------------

注意是单选题哦！前5名答对的站友有丁当奖励哦，大家积极参与吧～